Compare RANI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | ADVB |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 109.2M |
| IPO Year | 2021 | N/A |
| Metric | RANI | ADVB |
|---|---|---|
| Price | $1.37 | $4.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.60 | N/A |
| AVG Volume (30 Days) | ★ 804.8K | 124.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.05 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,028,000.00 | N/A |
| Revenue This Year | $414.59 | N/A |
| Revenue Next Year | $30.15 | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.19 |
| 52 Week High | $3.87 | $5.69 |
| Indicator | RANI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 90.72 |
| Support Level | $1.31 | $0.41 |
| Resistance Level | $1.42 | $5.69 |
| Average True Range (ATR) | 0.08 | 0.52 |
| MACD | 0.02 | 0.29 |
| Stochastic Oscillator | 80.95 | 78.52 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.